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Abstract
Background:  The analysis of gene sets has become a popular topic in recent times, with
researchers attempting to improve the interpretability and reproducibility of their microarray
analyses through the inclusion of supplementary biological information. While a number of options
for gene set analysis exist, no consensus has yet been reached regarding which methodology
performs best, and under what conditions. The goal of this work was to examine the performance
characteristics of a collection of existing gene set analysis methods, on both simulated and real
microarray data sets. Of particular interest was the potential utility gained through the
incorporation of inter-gene correlation into the analysis process.
Results: Each of six gene set analysis methods was applied to both simulated and publicly available
microarray data sets. Overall, the various methodologies were all found to be better at detecting
gene sets that moved from non-active (i.e., genes not expressed) to active states (or vice versa),
rather than those that simply changed their level of activity. Methods which incorporate correlation
structures were found to provide increased ability to detect altered gene sets in some settings.
Conclusion: Based on the results obtained through the analysis of simulated data, it is clear that
the performance of gene set analysis methods is strongly influenced by the features of the data set
in question, and that methods which incorporate correlation structures into the analysis process
tend to achieve better performance, relative to methods which rely on univariate test statistics.
Background
Gene expression microarrays provide a snapshot of gene
transcript abundance on a genomic scale, and are a popu-
lar tool for detecting differences in gene activity across
biological samples. While many currently used
approaches for analyzing microarray data focus on
detach-detecting changes in activity on a per-gene basis
[1,2], biological processes are generally the result of inter-
actions between multiple genes (i.e., a gene pathway or a
network), and are thus not easily interrogated via single
gene methods. To facilitate such analyses, statistical meth-
ods have been developed which focus on detecting
changes in groups of functionally related genes, thus
allowing additional biological information to be incorpo-
rated into the analysis process [3-9]. Despite commonality
of purpose, these methods take quite different approaches
to achieving their goal, and can thus produce differing
results when applied to the same data set. Recently Goe-
man [10] discussed the assumptions underlying these dif-
fering methodologies. Here we attempt to examine the
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performance differences between a number of methods
through the analysis of real and simulated microarray
data sets. In order to allow meaningful comparisons to be
made, methods were selected for which software packages
were available through the Bioconductor project [11], so
that the ways by which gene sets were defined, and multi-
ple comparisons corrections were performed could be
strictly controlled, so as to ensure consistency across
methods.
The basic goal of each of the methods investigated here is
the same, to detect statistically significant changes in the
expression activity of groups of genes. A necessary ingredi-
ent in the analysis process, therefore, is a collection of
gene sets. These can be obtained in a number of ways. The
first of these involves the use of publicly available annota-
tion information such as that provided by the Kyoto Ency-
clopedia of Genes and Genomes (KEGG) [12], Gene
Ontology [13], GenMAPP [14] and ResNet [15] databases.
Taking this approach organizes genes into (possibly over-
lapping) groups which share common functional annota-
tion, that is, sets of genes that are considered to be
involved in the same underlying biological process.
Although the assignment of genes to functional categories
in this way is somewhat contentious (many factors influ-
ence the roles genes play in biological processes, so gene
function is very much context-specific), it is currently (and
will likely continue to be) a popular method for investi-
gating the regulation of specific biological functions.
While other methods for defining gene sets certainly exist
(e.g., selecting highly correlated clusters of genes, inde-
pendent of functional annotation), here we have chosen
to employ a single, well-used approach, and focus on
exploring the performance characteristics associated with
each of the following analytic methods.
Gene Set Enrichment Analysis (GSEA)
Currently the most well-known and widely used approach
to gene set analysis, the GSEA method was introduced by
Mootha et al. [3], and was used to identify pre-defined
gene sets which exhibited significant differences in expres-
sion between samples from normal and diabetic patients.
The methodology was subsequently refined by Subrama-
nian et al. [4]. In this approach, genes are ranked by their
signal-to-noise ratio (SNR) (the difference in means of the
two class divided by the sum of the standard deviations of
the two classes), and a "running sum" statistic is calcu-
lated for each gene set, based on the ranks of the members
of the set, relative to those of the non-members. The max-
imum of this running sum across all genes is defined to be
the "enrichment score" (ES). A high ES is achieved when
a gene set contains a large number of highly ranked genes.
A permutation-based p-value is then calculated for each
gene set which is used to identify significant alterations in
expression across experimental conditions. Bioconductor
[11] includes two packages which implement the GSEA
methodology, Category (implemented as specified in [16]
with a modification to calculate the absolute value of per-
gene test statistics) and limma [17], although there are
some differences between the two, particularly in the way
in which permutation-based p-values are calculated. In
the Category package p-values are determined based on
summing the t-statistics for the members of each gene set,
while the limma package uses the mean of the t-statistics
(i.e., essentially identical statistics, except for a scaling fac-
tor based on gene set size). In addition, the Category pack-
age computes p-values based on permutation of the
sample labels, whereas the limma package uses permuta-
tion of gene labels. The relationship between these differ-
ing approaches to permutation and the underlying
hypotheses being investigated are discussed in detail by
Tian et al. [6], and by Goeman and Buhlmann [10], the
latter of whom refer to tests as being either "self-con-
tained" (samples permuted) or "competitive" (genes per-
muted).
Significance Analysis of Function and Expression (SAFE)
The GSEA method was generalized and extended via the
SAFE procedure [5] by taking a two-stage permutation-
based approach to assessing significant changes in gene
expression across experimental conditions. To accomplish
this, the SAFE methodology utilizes the concept of local
and global statistics. The local statistic measures the associ-
ation between gene expression profiles and clinical out-
comes, on a per-gene basis, generally using t-like statistics,
or similar (essentially an alternative to the SNR employed
by the original GSEA methodology [3]). The global statis-
tic is then used to assess how the distribution of local sta-
tistics within a gene set differs to those outside the set. The
Wilcoxon rank sum and Kolmogorov-Smirnov statistics
are examples of possible global statistics, with the Wil-
coxon rank sum statistic providing a similar setup to the
original GSEA implementation [3]. Permutation of sam-
ples is then used to generate a p-value for the global statis-
tic for each gene set. This methodology is implemented in
the safe package, available through Bioconductor [11].
Globaltest
The Globaltest methodology was introduced by Goeman
et al. [7], and was designed to determine whether the com-
mon expression pattern of genes within a pre-defined set
is significantly related to clinical outcome. Unlike the
GSEA and SAFE procedures, no univariate per-gene statis-
tics are utilized, instead a generalized linear model is used
to estimate a "Q-statistic" for each gene set, which
describes the correlation between gene expression pro-
files, X, and clinical outcomes, Y. The Q-statistic for a gene
set is the average of the Q-statistics for each gene in the set.
An inter-sample covariance matrix is used for calculation
of the Q-statistic, which provides increased computa-BMC Bioinformatics 2008, 9:502 http://www.biomedcentral.com/1471-2105/9/502
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tional efficiency when testing gene sets that contain large
numbers of genes.
Principal Coordinates and Hotelling's T2 (PCOT2)
This approach combines dimension reduction via Princi-
pal Coordinates [18] with Hotelling's multivariate exten-
sion of the t-test [19]. Versions of this approach were
independently developed by Kong et al. [8] and Song et al.
[20], with the pcot2 package [20] providing this function-
ality within Bioconductor. For each gene set, principal
coordinates (PCO) is used to perform dimension reduc-
tion, allowing the possibly high-dimensional gene set
data to be represented in low-dimensional space (e.g., two
or three dimensions). This effectively creates a small
number of meta-genes (linear combinations of the mem-
bers of the gene set) which are assessed for changes in
expression level across treatment conditions. The advan-
tage of using PCO is that the inter-gene correlation struc-
ture is automatically incorporated into the process of
dimension reduction, so this information is not lost. The
use of Hotelling's T2 procedure then allows this correla-
tion (which is now represented as correlations between
the lower dimensional meta-genes) to be included in the
test statistic for each gene set. Like the Globaltest
approach, the PCOT2 methodology generates a statistic
for each gene set without the use of per-gene summaries.
sigPathway
This methodology was developed by Tian et al. [6], and is
used to test whether a group of genes is coordinately asso-
ciated with a clinical outcome. Two possible null hypoth-
eses to be tested are described in the paper: the first tests
whether members of a gene set show the same pattern of
association with a phenotype as non-members, while the
second tests whether the expression patterns exhibited by
members of a gene set are associated with the phenotype.
As the second form of the null hypothesis reflects the
default test used by all other gene set analysis methods
investigated in this work (except for GSEA-limma), this
was selected for use here. For each gene set a test statistic
based on the average of the t statistics for each member
gene is calculated. A permutation-based method is then
used to generate the appropriate null distribution (genes
for the first version of the null hypothesis, samples for the
second version) for the test statistics, allowing p-values to
be calculated. By default, the sigPathway approach uses a
q-value approach to control the false discovery rate, how-
ever here the Benjamini and Yekutieli [21] correction was
applied to the raw p-values produced by the calculate.NEk
function so as to maintain consistency with the other
methods used in this work. This methodology is imple-
mented in the sigPathway package from Bioconductor
[11].
Gene set test statistics
Table 1 provides a summary of the default statistical meth-
odology used to describe the changes observed in each
gene set by these analysis methods, with t statistics provid-
ing the default per-gene summary for all methods
employing univariate statistics. With the exception of the
SAFE (which uses ranks of t statistics), all methods utiliz-
ing t statistics are essentially producing the same summary
for each gene set, and thus any differences in performance
must reflect differences in the approach for determining
statistical significance of altered gene sets. The perform-
ance of each of these gene set analysis methods was
assessed through the use of simulated data sets, the results
of which are presented in the next section. In addition,
two publicly available microarray data sets were analyzed
using each of the methods.
Results
Performance on simple simulated data
The simulated data sets contained 40 microarrays, each
consisting of 20 control and 20 treated samples. Four dif-
ferent types of gene set activity were simulated independ-
ently: (1) Off-Off (ND): Gene sets were inactive (i.e.,
genes within the group were not expressed) in both classes
(control and treatment) with no difference (ND) in gene
expression occurring between classes; (2)On-Off (D):
Gene sets were active (i.e., genes co-expressed) in one class
but not in the other, thus generating a difference (D)
between the means of the genes in the set, across the two
classes; (3) On-On (ND): Gene sets were active in both
classes but with no difference (ND) in expression activity;
(4) On-On (D): Gene sets were active in both classes, with
a difference (D) between the means of the member genes,
across the two classes. In this simulation a total of 400
genes were used, spread across 20 non-overlapping gene
sets, with 20 genes per gene set.
Table 1: Summary of measurements used for each gene set method.
Method Measurement of gene set Permutation
GSEA-Category The sum of the T-statistics Sample
GSEA-limma The mean of the T-statistics Gene
SAFE The sum of the ranks of the T-statistics Sample
Globaltest The mean of the Q-statistics Sample
PCOT2 Hotelling's T2 (multivariate T-statistic) Sample
sigPathway The mean of the T-statistics SampleBMC Bioinformatics 2008, 9:502 http://www.biomedcentral.com/1471-2105/9/502
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Gene set activity was simulated in the following propor-
tions for each data set: 0.4 Off-Off (ND), 0.2 On-Off (D),
0.2 On-On (ND) and 0.2 On-On (D), with the multivari-
ate normal distribution used to generate data from active
(ON) gene sets (to allow co-expression, and hence corre-
lation), and a standard normal distribution (mean 0,
standard deviation 1) used to generate data from inactive
(OFF) gene sets (no expression, so no correlation possi-
ble).
The results of applying each of the six gene set analysis
methods to a collection of 100 of these small simulated
microarray data sets are presented in Table 2, where the
values in each cell relate to the proportion of gene sets
exhibiting of each type of expression activity [On-Off (D),
On-On (D), Off-Off (ND), On-On (ND)] that were cor-
rectly identified by each of the methods. For the simula-
tion an inter-mean difference of 0.5 was used in
conjunction with a pairwise correlation between genes of
0.1. For each method 10,000 permutations were used to
generate p-values for each gene set. The results show that
the GSEA-Category, Globaltest and PCOT2 methods were
able to detect more of the gene sets exhibiting altered
expression [On-Off (D) and On-On (D)] than the SAFE,
GSEA-limma and sigPathway methods were, at a cost of
reporting slightly more false positives, corresponding to
lower proportions of correctly identified Off-Off (ND)
and On-On (ND) gene sets.
Figure 1 presents the detection rate for active gene sets as
a function of increasing inter-gene correlations, for two
different inter-class separations (inter-mean differences of
1 or 0.5), with 2,000 permutation used to generate p-val-
ues for each gene set. For well-separated classes (panels
(a) and (b), difference of 1), the GSEA-Category, Global-
test and PCOT2 methods all performed consistently well
across the range of correlations, while the GSEA-limma
and SAFE methods exhibited a drop in performance with
increasing inter-gene correlation. For a smaller separation
between the classes (panels (c) and (d), difference of 0.5),
the performance of GSEA-Category, Globaltest and
PCOT2 decreased with increasing correlation, but the per-
formance of the GSEA-limma and PCOT2 methods actu-
ally appeared to increase, although the detection ability of
these methods was still much lower than that of the top
three. The performance of the sigPathway method was
extremely poor on the simulated data, with this approach
unable to detect any altered pathways at these levels of
separation between the classes. Further investigation of
this revealed that the directionality of the changes
observed within the gene sets was a major factor in this
poor performance. When the simulation was repeated
using gene sets where all altered genes had the same direc-
tion of change (e.g.., all up-regulated), the performance of
the sigPathway method improved markedly. This suggests
that the test statistic generated for each gene set requires
consistent changes in expression by member genes, other-
wise the opposing changes tend to cancel each other out.
These results are presented in Additional file 1.
An interesting relationship amongst the six methods is
observed in Figure 2, which shows the effect of increasing
the amount of separation between the classes for fixed lev-
els of correlation (pairwise correlations of either 0.1 or
0.25), with 2,000 permutations again used to generate
gene set p-values. While both GSEA methods, along with
Globaltest, PCOT2 and sigPathway showed improved
performance with increasing inter-class separation, the
SAFE procedure actually exhibited worse performance.
While seemingly strange, it must be remembered that
SAFE operates on the ranks of genes, which do not take
the magnitude of the inter-class differences into account.
The sigPathway method can be seen to perform relatively
poorly at even moderate to high degrees of inter-class sep-
aration, however, this again appears to be the result of
genes exhibiting non-consistent changes (in terms of
direction) within the gene sets.
Table 2: Detection rates for the six gene set analysis methods on simple simulated data.
PCOT2 SAFE GSEA-Category GSEA-limma Globaltest sigPathway
On-Off (D) 0.902 0.236 0.912 0.24 0.93 0.002
(0.013) (0.021) (0.012) (0.019) (0.011) (0.002)
On-On (D) 0.858 0.22 0.85 0.268 0.886 0
(0.016) (0.019) (0.014) (0.019) (0.014) (0)
Off-Off (ND) 0.994 1 0.996 1 0.992 0.998
(0.003) (0) (0.003) (0) (0.005) (0.002)
On-On (ND) 0.99 1 0.994 1 0.992 1
(0.004) (0) (0.003) (0) (0.004) (0)
100 data sets (each containing 20 genes in 20 sets) were analyzed by each method, with 10,000 permutations used to generate p-values to which 
FDR controlling adjustments [21] were made. An adjusted p-value of 0.05 was required for significance. The value in each cell relates to the 
proportion of each type of gene set activity correctly identified by each method. Standard errors are shown in parentheses.BMC Bioinformatics 2008, 9:502 http://www.biomedcentral.com/1471-2105/9/502
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Detection rates in simulated data sets as a function of increasing correlation Figure 1
Detection rates in simulated data sets as a function of increasing correlation. For each gene set analysis method, the 
data were permuted 2,000 times to generate p-values for each gene set, within each simulation. FDR-adjusted p-values of less 
than 0.05 were used to indicate significance. (a) Gene sets active in one class and inactive in the other, On-Off (D), with a dif-
ference between the means of 1. (b) Gene sets active in both classes, On-On (D), with a difference between the means of 1. (c) 
Gene sets active in one class and inactive in the other, On-Off (D), with a difference between the means of 0.5. (d) Gene sets 
active in both classes, On-On (D), with a difference between the means of 0.5.BMC Bioinformatics 2008, 9:502 http://www.biomedcentral.com/1471-2105/9/502
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Detection rates in simulated data sets as a function of increasing inter-class separation Figure 2
Detection rates in simulated data sets as a function of increasing inter-class separation. For each gene set analysis 
method, the data were permuted 2,000 times to generate p-values for each gene set, within each simulation. FDR-adjusted p-
values of less than 0.05 were used to indicate significance. (a) Gene sets active in one class and inactive in the other, On-Off 
(D), with pairwise correlations of 0.1. (b) Gene sets were active in both classes, On-On (D), with pairwise correlations of 0.1. 
(c) Gene sets active in one class and inactive in the other, On-Off (D), with pairwise correlations of 0.25. (d) Gene sets were 
active in both classes, On-On (D), with pairwise correlations of 0.25.BMC Bioinformatics 2008, 9:502 http://www.biomedcentral.com/1471-2105/9/502
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Simulations based on microarray data
Each of the six gene set analysis methods were next used
to analyze a more complex collection of simulated data
sets, the structure of which (in terms of inter-class separa-
tion, and inter-gene correlation) was based on that of two
publicly available microarray data sets, one relating to dia-
betes [3], and the other to leukemia [22]. These data sets
were used to provide realistic values for the parameters p,
μ and Σ in (1). Distributions of the average μ and Σ (in
terms of pairwise correlations) values for each gene set are
shown in Additional files 2 and 3, for the two data sets uti-
lized.
The first data set was the diabetes data published by
Mootha et al. [3] with the introduction of the GSEA meth-
odology. These data contain expression information on
22,283 genes in skeletal muscle biopsy samples from 43
age-matched males: 17 with normal glucose tolerance
(NGT), 9 with impaired glucose tolerance (IGT) and 17
with type 2 diabetes mellitus (DM2). In the analysis pre-
sented here, only the 34 samples relating to the NGT and
DM2 classes were used. In addition to the microarray
data, Mootha et al. [3] also provide the 150 gene sets used
in the initial GSEA analysis (available on-line at http://
www.broad.mit.edu/publications/broad991s). These lists
were used to define the gene sets used in the analyses pre-
sented here, so that all six methods produced results based
on exactly the same collection of gene sets.
The second microarray data set used was the leukemia
data originally published by Golub et al. [22]. This data
consists of 34 samples: 20 from patients with acute lym-
phoblastic leukemia (ALL) and 14 from patients with
acute myeloid leukemia (AML). These data are publicly
available as the golubEsets Bioconductor package [11].
For the leukemia data, the Bioconductor annotation pack-
age hu6800 was used to define 134 gene sets relating to
KEGG pathways http://www.genome.ad.jp/kegg/ used in
the analysis. As for the diabetes data, the same collection
of gene sets was used by each of the six analysis methods.
Variance stabilization [23] was applied to the data using
the vsn Bioconductor package so as to maintain consist-
ency with a previous gene set analysis of these data [24].
As both data sets utilized the Affymetrix Genechip tech-
nology, a number of genes were represented by multiple
probe sets, potentially giving these genes more weight in
the analysis. To avoid this problem, the probe set median
was calculated for any gene represented by more than one
probe set. To restrict attention to gene sets of a reasonable
size, gene sets with less than 10 members were excluded
from the analysis. This resulted in the diabetes data set
Table 3: Detection rates for the six gene set analysis methods on realistic simulated data sets.
Simulations based on diabetes data [3]
PCOT2 SAFE GSEA-Category GSEA-limma Globaltest sigPathway
On-Off [D] 0.997 0.637 1 0.587 1 0.773
(0.003) (0.031) (0) (0.019) (0) (0.024)
On-On [D] 0.07 0.007 0.063 0 0.087 0.047
(0.013) (0.005) (0.015) (0) (0.017) (0.012)
Off-Off [ND] 0.993 1 0.997 1 0.997 0.997
(0.003) (0) (0.002) (0) (0.002) (0.002)
On-On [ND] 0.997 1 1 1 0.997 1
(0.003) (0) (0) (0) (0.003) (0)
Simulations based on leukemia data [22]
PCOT2 SAFE GSEA-Category GSEA-limma Globaltest sigPathway
On-Off [D] 1 0.384 0.998 0.552 1 0.966
(0) (0.031) (0.002) (0.021) (0) (0.007)
On-On [D] 0.5 0 0.444 0 0.584 0.18
(0.023) (0) (0.022) (0) (0.023) (0.017)
Off-Off [ND] 0.997 1 0.998 1 0.99 0.995
(0.001) (0) (0.001) (0) (0.003) (0.002)
On-On [ND] 0.994 1 0.99 1 0.99 0.996
(0.003) (0) (0.004) (0) (0.004) (0.003)
100 data sets were simulated, with gene numbers and gene set membership determined by data-specific values derived from the diabetes [3] and 
leukemia [22] data sets. The simulated data sets were analyzed by each gene set analysis method, with 2,000 permutations used to generate p-
values to which FDR controlling adjustments were made. An adjusted p-value of 0.05 was required for significance. The value in each cell relates to 
the proportion of each type of gene set activity correctly identified by each method. Standard errors are shown in parentheses.BMC Bioinformatics 2008, 9:502 http://www.biomedcentral.com/1471-2105/9/502
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retaining 3728 genes in 87 gene sets, and the leukemia
data retaining 2383 genes in 127 gene sets.
For each data set, values were obtained (p) or estimated
(μ, Σ) for each gene set, and 100 data sets were simulated
using (1), with each then analyzed using the six gene set
analysis methods.
Table 3 contains the results of applying each of the gene
set analysis methods to these simulated data sets. This
approach to simulation resulted in a major difference in
the degree of inter-class separation across the two data
sets, with the simulated gene sets based on the diabetes
data exhibiting far smaller changes in expression than
those based on the leukemia data (reflecting the different
structure of these data sets). As a result there was a sub-
stantial drop in the ability of all methods to detect
changes in gene sets that were active in both classes in the
diabetes data, as compared to the leukemia data. In both
cases, however, all methods were more successful at
detecting changes relating to gene sets switching from
being inactive to active between classes, than detecting
expression alterations in gene sets that were active in both
classes. Across both simulations, the two methods that
incorporate correlation information (Globaltest and
PCOT2) correctly identified the most differentially
expressed gene sets, which suggests that accounting for
correlation is an important issue in gene set analyses.
Analysis of microarray data
In order to investigate the similarity (in terms of gene sets
detected as having significantly altered expression) across
approaches, the six gene set analysis methods were
applied to each of the two publicly available microarray
data sets described above, the diabetes data set analyzed
by Mootha et al. [3] and the leukemia data set of Golub et
al. [22]. The results for the diabetes data are presented in
Table 4 and Additional file 4. As in the original analysis of
this data, the Oxidative Phosphorylation gene set
(OXPHOS_HG-U133A_probes) was identified by both
implementations of the GSEA procedure as being the gene
set most likely to have undergone a change in expression
activity. Interestingly, however, GSEA-limma was the only
approach that reported this change to be significant after
correction for multiple testing. The most likely explana-
tion for this is that the GSEA-limma methodology defaults
to permuting genes in the calculation of p-values, and is
essentially testing a different null hypothesis (as described
by Tian et al. [6]). The significance noted here, therefore,
can be interpreted to mean that the genes contains in the
OXPHOS_HG-U133A_probes gene set are significantly
more different across classes than genes that are not mem-
bers of that gene set, but that the degree of separation
between the classes could still have been observed by
chance (based on the non-significance of the GSEA-Cate-
gory p-value). Figure 3 contains a graphical summary of
the gene activity relating to the Oxidative Phosphoryla-
tion gene set, and was produced using the functionality of
the pcot2 Bioconductor package [20]. Information on
intra-class correlation, absolute expression, and differen-
Table 4: Application of gene set analysis methods to diabetes 
data [3].
Top Pathways NP AP
GSEA-Category
OXPHOS_HG-U133A_probes 0.071 1
MAP00480_Glutathione_metabolism 0.091 1
MAP00500_Starch_and_sucrose_metabolism 0.19 1
MAP00252_Alanine_and_aspartate_metabolism 0.199 1
GLUCO_HG-U133A_probes 0.202 1
...... ... ...
GSEA-limma
OXPHOS_HG-U133A_probes <0.001 <0.001
c18_U133_probes 0.004 0.88
Human_mitoDB_6_2002_HG-U133A_probes 0.006 0.88
Mitochondr_HG-U133A_probes 0.01 1
MAP00190_Oxidative_phosphorylation 0.018 1
...... ... ...
SAFE
MAP00561_Glycerolipid_metabolism 0.011 1
OXPHOS_HG-U133A_probes 0.021 1
MAP00500_Starch_and_sucrose_metabolism 0.035 1
MAP00240_Pyrimidine_metabolism 0.046 1
GLUCO_HG-U133A_probes 0.049 1
...... ... ...
GlobalTest
MAP00252_Alanine_and_aspartate_meta... 0.106 1
OXPHOS_HG-U133A_probes 0.123 1
c23_U133_probes 0.14 1
c25_U133_probes 0.144 1
GLUCO_HG-U133A_probes 0.144 1
...... ... ...
PCOT2
c20_U133_probes 0.032 1
OXPHOS_HG-U133A_probes 0.045 1
MAP00190_Oxidative_phosphorylation 0.06 1
FA_HG-U133A_probes 0.086 1
c28_U133_probes 0.093 1
...... ... ...
sigPathway
c22_U133_probes 0.012 1
c29_U133_probes 0.014 1
OXPHOS_HG-U133A_probes 0.014 1
c25_U133_probes 0.032 1
MAP00252_Alanine_and_aspartate_metabolism 0.088 1
...... ... ...
Top five altered gene sets determined by each of the six analysis 
methods. NP indicates the nominal p-values and AP indicates the FDR 
adjusted p-values.BMC Bioinformatics 2008, 9:502 http://www.biomedcentral.com/1471-2105/9/502
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tial expression is presented. Here it can be observed that a
subset of genes within the OXPHOS_HG-U133A_probes
gene set exhibit tightly correlated expression patterns
within the NGT class, and that most of these probes are
down-regulated in the DM2 class (with a subsequent
decrease in correlation).
The results for the leukemia data are presented in Table 5
and Additional file 5. Based on the adjusted p-values, all
methods except SAFE were able to identify gene sets with
significantly altered expression activity. The remaining
approaches reported 2 (GSEA-limma), 72 (GSEA-Cate-
gory), 67 (PCOT2), 77 (Globaltest) and 7 (sigPathway)
significantly altered gene sets. The overlap between the
latter four of these methods is presented in Figure 4, with
57 gene sets detected in common by three approaches
(GSEA-Category, PCOT2 and Globaltest). Of these 57, 7
were also detected by sigPathway, mirroring the results of
the simulation analysis in terms of the similarity of per-
formance between these approaches. There is also a high
level of agreement between the Globaltest and PCOT2
methods, with 63 gene sets detected in common, which
most likely reflects the similarity of these approaches (in
terms of the incorporation of correlation information),
Visualization of expression and correlation in the OXPHOS HG-U133A probes pathway using the pcot2 package Figure 3
Visualization of expression and correlation in the OXPHOS HG-U133A probes pathway using the pcot2 pack-
age. The four red-blue plots represent pairwise correlations between genes in the pathway, with positively correlated genes 
clustered together. The top left plot relates to the inter-gene correlations observed within the DM2 samples, while the top 
right plot contains the inter-gene correlation information for the NGT samples, with genes in the same order as the top left plot 
(i.e., the gene order is the same in both plots on the top row). The same approach is taken in the bottom two plots, with the 
bottom right plot representing inter-gene correlation within the NGT samples, with genes again grouped by correlation. The 
gene order in the bottom left plot (DM2 samples) is then the same as that in the bottom right. The gray-scale plots in the 
center of the figure indicate gene expression intensity, while the red-green plots show the change in expression level (red indi-
cates up-regulation in DM2 relative to NGT).BMC Bioinformatics 2008, 9:502 http://www.biomedcentral.com/1471-2105/9/502
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and again reinforces the close agreement observed in the
simulated data sets. In order to further explore the lower
detection rate of the sigPathway approach, the expression
patterns of the genes within the 57 common gene sets
were examined. Within the 7 gene sets detected by sig-
Pathway, on average, 71% of genes exhibited altered
expression in the same direction, whereas in the remain-
ing 50 gene sets the average was only 58%, further suggest-
ing that the Bioconductor implementation of sigPathway
requires members of altered gene sets to exhibit changes
in a consistent direction.
Table 5: Application of gene set analysis methods to leukemia data [22].
Top Pathways NP AP
GSEA-Category
Glycolysis/Gluconeogenesis <5e-05 <5e-05
Focal adhesion <5e-05 <5e-05
Tight junction <5e-05 <5e-05
Leukocyte transendothelial migration <5e-05 <5e-05
Regulation of actin cytoskeleton <5e-05 <5e-05
...... ... ...
GSEA-limma
Hematopoietic cell lineage <5e-05 0.034
B cell receptor signaling pathway <5e-05 0.034
Glutathione metabolism 0.017 1
Glycolysis/Gluconeogenesis 0.025 1
Natural killer cell mediated cytotoxicity 0.028 1
...... ... ...
SAFE
Natural killer cell mediated cytotoxicity 0.0052 1
Glycolysis/Gluconeogenesis 0.00835 1
Galactose metabolism 0.0128 1
Pyrimidine metabolism 0.0333 1
Cell cycle 0.0353 1
...... ... ...
GlobalTest
Toll-like receptor signaling pathway <5e-05 <5e-05
Jak-STAT signaling pathway <5e-05 <5e-05
Focal adhesion <5e-05 <5e-05
Tight junction <5e-05 <5e-05
Leukocyte transendothelial migration <5e-05 <5e-05
...... ... ...
PCOT2
Jak-STAT signaling pathway <5e-05 0.001
Glycolysis Gluconeogenesis <5e-05 0.001
Focal adhesion <5e-05 0.001
Tight junction <5e-05 0.001
Hematopoietic cell lineage <5e-05 0.001
...... ... ...
sigPathway
Arachidonic acid metabolism <5e-05 0.001
Metabolism of xenobiotics by cytochrome P450 <5e-05 0.004
Glutathione metabolism <5e-05 0.009
Cell cycle 0.0001 0.016
Starch and sucrose metabolism 0.0002 0.023
...... ... ...
Top five altered gene sets determined by each of the six analysis methods. NP indicates the nominal p-values and AP indicates the FDR adjusted p-
values.BMC Bioinformatics 2008, 9:502 http://www.biomedcentral.com/1471-2105/9/502
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Significant gene sets detected in the leukemia data set (GSEA-Category, Globaltest, PCOT2, sigPathway) Figure 4
Significant gene sets detected in the leukemia data set (GSEA-Category, Globaltest, PCOT2, sigPathway). (a) 
The GSEA-Category, Globaltest and PCOT2 approaches detected 72 (GSEA-Category), 77 (Globaltest) and 67 (PCOT2) gene 
sets as undergoing significant changes in expression activity, after correction for multiple testing, with 57 gene sets detected as 
significantly altered by all three approaches. The two methods which incorporate correlation structure into their assessment 
procedure (Globaltest and PCOT2) exhibited strong agreement in the gene sets they found to be altered (63 significant gene 
sets in common). (b) Of the 57 changed gene sets identified in common by GSEA-Category, Globaltest and PCOT2, 7 were 
also found by sigPathway.BMC Bioinformatics 2008, 9:502 http://www.biomedcentral.com/1471-2105/9/502
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Discussion
Gene set analysis has become an important aspect of the
analysis and interpretation of gene expression microarray
data. Despite the availability of a number of different gene
set analysis methodologies, there is currently very little
information on their relative merits. Here we have inves-
tigated the performance characteristics of a subset of com-
monly used approaches through the analysis of both
simulated and real microarray data. A recent paper by Liu
et al. [9] used a similar approach to investigate the per-
formance of three different gene set analysis methods, one
of which was the version of Globaltest implemented here.
The simulated data generated in that publication were
also based on a multivariate normal distribution,
although parameters were specified by the authors (as in
the first simulation presented here), rather than being
based on estimates derived from real microarray data sets
(as in the second simulation in this work). The main find-
ing of the work by Liu et al. [9] was that the results
achieved by the three approaches investigated were
broadly similar, particularly when standardization meth-
ods were applied to the data. In contrast, for the method-
ologies examined here, we found substantial differences
in performance between approaches in both the simula-
tion studies that were performed. The most likely reason
for these differences relates to the gene set analysis meth-
ods that were investigated. The study by Liu et al. [9] com-
pared the performance of two methods based on the
Globaltest methodology (Global Test, and ANCOVA Glo-
bal Test [25]), and one (SAM-GS [26]) that was very simi-
lar (in that it utilized a t-like statistic followed by sample
permutation) to the implementation of GSEA in the cate-
gory package that was used here. Given the high concord-
ance between Globaltest and GSEA-Category that was
observed in this study, it is reassuring that the three meth-
ods presented by Liu et al. [9] gave good agreement with
one another. In addition, the supplementary data pro-
vided in that paper included performance data for a com-
petitive (i.e., permutation of genes) version of GSEA that
exhibited lower power than Globaltest. The same relation-
ship was observed here when comparing Globaltest to the
GSEA-limma methods, which also involved gene permu-
tation.
Based on our results, we feel that of the six approaches
examined, the GSEA (as implemented in the Category
package [16]), Globaltest and PCOT2 methodologies all
exhibited similar performance in the situations explored
here, with the correlation-based methods (Globaltest and
PCOT2) offering slightly better performance in some set-
tings. The fact that the GSEA-Category approach was able
to perform well in the presence of inter-gene correlation
(despite it not explicity using this information), most
likely reflects the relatively low within-class correlation
levels that were observed. That is, the Globaltest and
PCOT2 approaches did not seem to gain a major advan-
tage through their use of correlation structures in the set-
tings explored here.
The SAFE methodology, the limma implementation of
GSEA, and the sigPathway method, emerged as perform-
ing relatively poorly in this analysis. For the SAFE meth-
odology, this is due to the rank-based system employed by
default in the safe package, which fails to take the magni-
tude of the separation between classes into account. For
gene sets containing a collection of genes for which a large
degree of separation is present between classes, permuta-
tion will still tend to result in these genes having highly
ranked t-statistics, as many permutations will still produce
a substantial degree of interclass separation, due to the
large difference between the class means. Because of this,
gene sets exhibiting large differences across classes can still
produce large test statistics under permutation when a
rank-based method is used to summarize gene set activity,
whereas a statistic that does not use ranks (e.g., taking the
mean of the per-gene t-statistics for a gene set) will be
much less likely to produce a permutation-based test sta-
tistic of the same magnitude as that generated from the
original data.
For the GSEA-limma approach, the choice to permute
genes rather than samples in the calculation of p-values
for each gene set appears to be the dominant difference
between this method and that of the GSEA-Category
implementation, and is therefore highly likely to explain
the difference in performance. The decision on whether to
permute rows or columns of the data matrix obviously
reflects a difference in the null hypothesis being investi-
gated, and must therefore be considered by individual
researchers. For the sigPathway method, our additional
investigations have revealed that consistency in the direc-
tion of expression changes is required for the detection of
significantly altered gene sets, and this can largely explain
the lower detection rate exhibited by this approach.
The incorporation of correlation into the analytic process
by the Globaltest and PCOT2 approaches reflects a step
forward in gene set analysis methodologies. Correlation
has recently "re-emerged" as an important measure of
inter-gene relatedness, and forms the basis for the very
active field of regulatory network construction [27-29].
The ability to incorporate information about likely co-reg-
ulation (rather than simple co-expression) into the analy-
sis process serves as a useful surrogate for functional
relatedness, and thus adds to the biological interpretabil-
ity of the results. It also raises the possibility of defining
gene sets by observed (within-class) correlation structure,
rather than by functional relationship (as defined by pub-
lic databases). Such an approach allows the data to drive
the grouping of genes (as in the early days of microarrayBMC Bioinformatics 2008, 9:502 http://www.biomedcentral.com/1471-2105/9/502
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data analysis, where hierarchical clustering often used to
assign genes to groups exhibiting similar expression pat-
terns), which can then be tested for changes in expression
across classes, before being mapped back to functional
classes, thus avoiding a bias in gene set construction
induced by the database information (which is often
skewed towards commonly investigated genes, tissues,
organisms and diseases). With the presentation of these
results, we hope that researchers will now have an under-
standing of the relative performance of some of the com-
monly used gene set analysis methods. To further this
understanding, as additional procedures are developed,
we encourage other authors to include comparative simu-
lation data of the type provided here to contrast the per-
formance of newly proposed methodologies with existing
gene set analysis techniques.
Methods
Data sets
In order to introduce an inter-gene correlation structure
into the simulated data, the multivariate normal distribu-
tion with mean μ and variance-covariance matrix Σ was
used to generate the data for each gene set, based on the
following density function:
where X = [x1, x2, , xp] is a p × 1 vector, and each element
of X is a random variable with the multivariate normal
distribution with dimensionality p. The correlation matrix
ρ can be obtained from the variance-covariance matrix Σ
by ρ = (V1/2)-1Σ(V1/2)-1 where V is the p × p variance matrix
of variable X. In the simulated data, the variance-covari-
ance matrix was equal to the correlation matrix, as the
diagonal entries in the variance-covariance matrix were all
equal to 1.
P-value calculation and multiple comparisons procedures
Each of the gene set analysis methods are able to produce
p-values which are uncorrected for multiplicity (i.e., nom-
inal or unadjusted p-values), based on the use of permu-
tation of either samples or genes. Here the default
permutation approach employed by each method was
used, except in the case of sigPathway (which returns
results for both sample and gene permutation) where the
outputs relating to sample permutation were utilized. In
order to remove any variability introduced through the
use of different multiple comparisons corrections, the
False Discovery Rate (FDR) controlling method of Ben-
jamini and Yekutieli [21] was used to provide control of
Type I errors when testing for changes in multiple gene
sets. This method of p-value adjustment was applied to the
nominal p-values produced by all of the gene set analysis
methods. For the small simulated data sets, 10,000 per-
mutations were used to generate p-values, while for both
the second (more complex) simulated data sets and
Mootha's microarray data set, 2000 permutations were
used. For Golub's data, 20,000 permutations were applied
to produce more finely grained p-values so as to better dif-
ferentiate top-ranked significantly changed pathways.
A FDR controlling approach was favored over more tradi-
tional methods of family-wise error rate control, as FDR-
based methodology is currently the most commonly used
approach for microarray analyses. The choice of the Ben-
jamini-Yekutieli FDR controlling method [21] reflects the
fact that correlation may exist between gene sets, and thus
test statistics, either because two gene sets are involved in
the same biological process, or because individual genes
appear in multiple gene sets. For all hypothesis tests, an
adjusted p-value of less than 0.05 was considered to indi-
cate a statistically significant change in gene set expres-
sion.
Implementation
All gene set analysis methods used in this paper are avail-
able as software packages through the Bioconductor
project http://www.bioconductor.org.
Authors' contributions
All data analysis was performed by SS. The manuscript
was prepared by SS and MAB. Both authors have read and
approved the final version of the manuscript.
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Additional file 1
Detection rates for the six gene set analysis methods on simple simu-
lated data. In contrast to Table 2, all altered gene sets were simulated so 
as to exhibit changes in the same direction. This resulted in a major per-
formance improvement for the sigPathway approach. 100 data sets (each 
containing 20 genes in 20 sets) were analyzed by each method, with 
10,000 permutations used to generate p-values to which FDR controlling 
adjustments [21] were made. An adjusted p-value of 0.05 was required 
for significance. The value in each cell relates to the proportion of each 
type of gene set activity correctly identified by each method. Standard 
errors are shown in parentheses.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2105-9-502-S1.pdf]
Additional file 2
The distribution of difference and pairwise correlations in diabetes 
data3[3]. (a) difference for each gene, positive value indicates up-regu-
lation in DM2 samples (b) average difference for each gene set (c) pair-
wise correlations for all gene pairs using DM2 samples (d) average 
pairwise correlations for each gene set using DM2 samples (e) pairwise 
correlations for all pairs of genes using NGT samples (f) average pairwise 
correlations for each gene set using NGT samples.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2105-9-502-S2.jpeg]BMC Bioinformatics 2008, 9:502 http://www.biomedcentral.com/1471-2105/9/502
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Additional file 3
The distribution of difference and pairwise correlations in the leuke-
mia data22[22]. (a) difference for each gene, positive value indicates up-
regulation in AML samples (b) average difference for each gene set (c) 
pairwise correlations for all gene pairs using AML samples (d) average 
pairwise correlations for each gene set using AML samples (e) pairwise 
correlations for all pairs of genes using ALL samples (f) average pairwise 
correlations for each gene set using ALL samples.
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Additional file 4
Application of gene set analysis methods to diabetes data3[3](all gene 
sets). Ranked (by p-value) gene sets produced by each of the six analysis 
methods. NP indicates the nominal p-values and AP indicates the FDR 
adjusted p-values.
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Additional file 5
Application of gene set analysis methods to leukemia data22[22](all 
gene sets). Ranked (by p-value) gene sets produced by each of the six 
analysis methods. NP indicates the nominal p-values and AP indicates the 
FDR adjusted p-values.
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